Product Images Entadfi

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Entadfi NDC 69681-125 by Veru Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

image of bottle label - 5 mg/5 mg - 30 tablets - 30ct

image of bottle label - 5 mg/5 mg - 30 tablets - 30ct

image of bottle label - 5 mg/5 mg - 30 tablets - 90ct

image of bottle label - 5 mg/5 mg - 30 tablets - 90ct

image of chemical structure of Tadalafil - cs1

image of chemical structure of Tadalafil - cs1

image of chemical structure of Finasteride - cs2

image of chemical structure of Finasteride - cs2

image of Mean Maximal Change in Blood Pressure (Tadalafil Minus Placebo, Point Estimate with 90% CI) in Response to Sublingual Nitroglycerin at 2 (Supine Only), 4, 8, 24, 48, 72, and 96 Hours after the Last Dose of Tadalafil 20 mg or Placebo - fig1

image of Mean Maximal Change in Blood Pressure (Tadalafil Minus Placebo, Point Estimate with 90% CI) in Response to Sublingual Nitroglycerin at 2 (Supine Only), 4, 8, 24, 48, 72, and 96 Hours after the Last Dose of Tadalafil 20 mg or Placebo - fig1

The text is presenting two tables of blood pressure readings, one for standing and the other for supine positions. The tables show the systolic and diastolic readings along with their differences. There is not enough information to determine the context or purpose of the tables.*

image of Doxazosin Study 1: Mean Change from Baseline in Systolic Blood Pressure - fig2

image of Doxazosin Study 1: Mean Change from Baseline in Systolic Blood Pressure - fig2

The text is describing a study that involves two groups of participants: one group taking Tadalafil 20mg and Doxazosin 8mg, and another group taking Placebo and Doxazosin 8mg. The study measures Supine Systolic BP (blood pressure in mmHg) over a period of time (6 to 18 hours post-dose) for both groups.*

image of Doxazosin Study 2 (Part C): Mean Change from Time-Matched Baseline in Systolic Blood Pressure - fig3

image of Doxazosin Study 2 (Part C): Mean Change from Time-Matched Baseline in Systolic Blood Pressure - fig3

image of Mean Total IPSS Changes By Visit in BPH Patients Taking Tadalafil Together with Finasteride - fig4

image of Mean Total IPSS Changes By Visit in BPH Patients Taking Tadalafil Together with Finasteride - fig4

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.